BELITE BIO, INC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.75 USD | +4.61% |
|
+18.91% | -13.11% |
| Apr. 26 | Belite Bio Unveils Plan to Offer 651,380 American Depository Shares | MT |
| Mar. 22 | Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 749.6 | 1,263 | 1,159 | - | - |
| Enterprise Value (EV) 1 | 749.6 | 1,263 | 1,096 | 1,118 | 1,159 |
| P/E ratio | -47.8 x | -38.4 x | -51.9 x | -48.3 x | -68.9 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 116 x | 185 x | 33.9 x |
| EV / Revenue | - | - | 110 x | 179 x | 33.9 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -29.7 x | -35.4 x | -45.8 x |
| FCF Yield | - | - | -3.37% | -2.83% | -2.18% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,867 | 27,599 | 29,149 | - | - |
| Reference price 2 | 30.14 | 45.75 | 39.75 | 39.75 | 39.75 |
| Announcement Date | 3/31/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10 | 6.25 | 34.13 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -12.82 | -31.69 | -29.51 | -25.78 | -20.75 |
| Operating Margin | - | - | - | -295.08% | -412.53% | -60.79% |
| Earnings before Tax (EBT) 1 | - | -12.65 | -31.62 | -29.51 | -25.78 | -20.75 |
| Net income 1 | -9.666 | -12.65 | -31.63 | -22.93 | -25.54 | -17.27 |
| Net margin | - | - | - | -229.28% | -408.62% | -50.59% |
| EPS 2 | -1.010 | -0.6300 | -1.190 | -0.7660 | -0.8225 | -0.5767 |
| Free Cash Flow 1 | - | - | - | -36.91 | -31.6 | -25.3 |
| FCF margin | - | - | - | -369.12% | -505.66% | -74.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 3/31/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | 12.5 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.78 | -1.78 | -6.881 | -6.871 | -10.96 | -6.975 | -7.5 | -7.067 | -7.567 | -6.9 | -6.5 |
| Operating Margin | - | - | - | - | - | - | - | - | - | -55.2% | - |
| Earnings before Tax (EBT) 1 | -1.73 | -1.73 | -6.889 | -6.809 | -10.93 | -6.991 | -7.5 | -7.067 | -7.567 | -6.9 | -6.501 |
| Net income 1 | -1.73 | -1.73 | -6.895 | -6.812 | -10.94 | -6.99 | -8.45 | -8.2 | -8.6 | 4.325 | -6.501 |
| Net margin | - | - | - | - | - | - | - | - | - | 34.6% | - |
| EPS 2 | -0.1200 | -0.1200 | -0.3300 | -0.2600 | -0.4000 | -0.2400 | -0.2850 | -0.2750 | -0.2875 | 0.1550 | -0.2000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/11/22 | 8/11/22 | 5/10/23 | 8/9/23 | 11/14/23 | 3/12/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 63.1 | 40.5 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -36.9 | -31.6 | -25.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.36 | 0.53 | 1.5 |
| Capex / Sales | - | - | - | 3.6% | 8.48% | 4.39% |
| Announcement Date | 3/15/22 | 3/31/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
39.75
USD
Average target price
56.5
USD
Spread / Average Target
+42.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.11% | 1.16B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BLTE Stock
- Financials Belite Bio, Inc
